Trial Profile
An Open-label, Long-term Study to Evaluate the Safety and Tolerability of BYM338 in Patients With Sporadic Inclusion Body Myositis
Status:
Discontinued
Phase of Trial:
Phase II/III
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Bimagrumab (Primary)
- Indications Inclusion body myositis
- Focus Adverse reactions; Registrational
- Sponsors Novartis
- 20 Jul 2020 Status changed from completed to discontinued as per Results published in the Neurology.
- 20 Jul 2020 Results published in the Neurology
- 06 Oct 2016 Status changed from active, no longer recruiting to completed.